Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, has announced another strategic deal at the 5th China International Import Expo (CIIE). This time, Organon is partnering with Alibaba Health Information Technology Ltd (HKG: 0241) to advance Internet-based medicine and chronic disease management.
Partnership Objectives
The collaboration aims to improve patient diagnosis and treatment compliance by leveraging Internet-based solutions. Alibaba Health will work with Organon on disease management, physician and patient education, and other areas focused on chronic diseases. The initial focus will be on cardiovascular diseases, with the goal of helping patients apply scientifically proven full-cycle management techniques and enjoy one-stop medical services enabled by AliHealth.
Future Prospects
This partnership underscores Organon’s commitment to enhancing healthcare outcomes through innovative collaborations. By combining Alibaba Health’s technology platform with Organon’s expertise in women’s health and chronic disease management, the collaboration aims to provide comprehensive and accessible healthcare solutions for patients in China.-Fineline Info & Tech
